Phase 3 Readout

NERV: Phase 3 Topline: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate

Name: Phase 3 Topline: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate
Start: 2028-12-01
End: 2028-12-01

December 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2028
Company: Minerva Neurosciences, Inc. (NERV)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate

December 1, 2028

NERV overview →

Company: Minerva Neurosciences, Inc. (NERV)
Indication: Negative Symptoms of Schizophrenia